Bullfrog AI Holdings, Inc. (BFRG) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Bullfrog AI Holdings, Inc. is a clinical-stage biopharmaceutical company focused on using its proprietary AI/ML platform, bfLEAP, to analyze complex data sets for drug asset enablement and precision medicine. The company operates as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 7, 2024, there were 7,850,550 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,611,646) | $(1,480,398) | $(3,515,440) | $(2,805,945) |
| Operating Expenses | $1,681,963 | $1,536,970 | $3,647,681 | $2,727,615 |
| Cash and Equivalents (End of Period) | $5,614,088 (as of June 30, 2024) | |||
| Total Liabilities | $691,493 (as of June 30, 2024) | |||
| Accumulated Deficit | $(13,287,138) (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue: The company generated no revenue in Q2 2024 or the first six months of 2024, consistent with the prior year periods.
- Operating Expenses: Total operating expenses increased by approximately 9.4% in Q2 2024 compared to Q2 2023, and by 33.7% on a year-to-date basis. This increase is primarily driven by higher personnel costs due to the hiring of technical staff and a Chief Science Officer, as well as increased stock-based compensation.
- Liquidity: Cash and cash equivalents increased significantly from $2.62 million at year-end 2023 to $5.61 million at June 30, 2024. This was driven by net proceeds of approximately $5.7 million from an underwritten secondary public offering in Q1 2024.
- Debt: The company has no long-term debt. Current liabilities include $341,040 in short-term insurance financing for Directors and Officers insurance premiums.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that in the absence of significant revenues, current capital resources are sufficient to fund planned operations for approximately 9 months from the date of filing. The company anticipates raising additional capital through equity sales, debt, or licensing agreements.
- Strategic Focus: The company is expanding target discovery efforts, engaging disease experts, and initiating preclinical studies (including an obesity study related to an siRNA program). They aim to monetize through strategic partnerships and by rescuing late-stage failed drugs.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in internal control over financial reporting. Remediation efforts are ongoing, including transitioning accounting processes to a new external firm and hiring a Corporate Controller.
- Risks: Key risks include the need for additional funding, the uncertainty of clinical trial outcomes, market acceptance of AI-driven drug discovery, and the potential inability to secure favorable terms for future financing.
Investor Verification Checklist
- Verify the timeline and terms of the planned capital raise required to extend operations beyond the 9-month runway.
- Monitor the progress of remediation efforts regarding the material weaknesses in internal controls over financial reporting.
- Review the status of the strategic data and commercialization agreement with the Lieber Institute for Brain Development (LIBD) for potential revenue milestones.
- Assess the burn rate relative to the $5.6 million cash balance and the impact of increasing R&D and G&A expenses.
- Check for updates on the preclinical obesity study and the status of licensed drug assets (e.g., Mebendazole formulations, Beta2-spectrin siRNA).